193 related articles for article (PubMed ID: 29535442)
1. Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D).
Aigner E; Feldman A; Neureiter D; Datz C; Ratziu V; Paulweber B
Am J Gastroenterol; 2018 Mar; 113(3):443-445. PubMed ID: 29535442
[No Abstract] [Full Text] [Related]
2. Long-term survival with sebelipase alfa enzyme replacement therapy in infants with rapidly progressive lysosomal acid lipase deficiency: final results from 2 open-label studies.
Vijay S; Brassier A; Ghosh A; Fecarotta S; Abel F; Marulkar S; Jones SA
Orphanet J Rare Dis; 2021 Jan; 16(1):13. PubMed ID: 33407676
[TBL] [Abstract][Full Text] [Related]
3. A Case of Lysosomal Acid Lipase Deficiency Confirmed by Response to Sebelipase Alfa Therapy.
Shen JJ; Davis JL; Hong X; Laningham FH; Gelb MH; Kim GE
J Pediatr Gastroenterol Nutr; 2020 Dec; 71(6):726-730. PubMed ID: 32740531
[TBL] [Abstract][Full Text] [Related]
4. Lysosomal acid lipase deficiency allograft recurrence and liver failure- clinical outcomes of 18 liver transplantation patients.
Bernstein DL; Lobritto S; Iuga A; Remotti H; Schiano T; Fiel MI; Balwani M
Mol Genet Metab; 2018 May; 124(1):11-19. PubMed ID: 29655841
[TBL] [Abstract][Full Text] [Related]
5. Sebelipase alfa improves atherogenic biomarkers in adults and children with lysosomal acid lipase deficiency.
Wilson DP; Friedman M; Marulkar S; Hamby T; Bruckert E
J Clin Lipidol; 2018; 12(3):604-614. PubMed ID: 29628368
[TBL] [Abstract][Full Text] [Related]
6. Sebelipase alfa: enzymatic replacement treatment for lysosomal acid lipase deficiency.
Paton DM
Drugs Today (Barc); 2016 May; 52(5):287-93. PubMed ID: 27376161
[TBL] [Abstract][Full Text] [Related]
7. Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency.
Frampton JE
Am J Cardiovasc Drugs; 2016 Dec; 16(6):461-468. PubMed ID: 27878737
[TBL] [Abstract][Full Text] [Related]
8. Sebelipase alfa: first global approval.
Shirley M
Drugs; 2015 Nov; 75(16):1935-40. PubMed ID: 26452566
[TBL] [Abstract][Full Text] [Related]
9. Early onset lysosomal acid lipase deficiency presenting as secondary hemophagocytic lymphohistiocytosis: Two infants treated with sebelipase alfa.
Santos Silva E; Klaudel-Dreszler M; Bakuła A; Oliva T; Sousa T; Fernandes PC; Tylki-Szymańska A; Kamenets E; Martins E; Socha P
Clin Res Hepatol Gastroenterol; 2018 Oct; 42(5):e77-e82. PubMed ID: 29705274
[TBL] [Abstract][Full Text] [Related]
10. Sebelipase alfa (Kanuma) for lysosomal acid lipase deficiency.
Med Lett Drugs Ther; 2016 Sep; 58(1504):e126-7. PubMed ID: 27649344
[No Abstract] [Full Text] [Related]
11. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance.
Thelwall PE; Smith FE; Leavitt MC; Canty D; Hu W; Hollingsworth KG; Thoma C; Trenell MI; Taylor R; Rutkowski JV; Blamire AM; Quinn AG
J Hepatol; 2013 Sep; 59(3):543-9. PubMed ID: 23624251
[TBL] [Abstract][Full Text] [Related]
12. Lysosomal acid lipase deficiency: diagnosis and treatment of Wolman and Cholesteryl Ester Storage Diseases.
Porto AF
Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():125-32. PubMed ID: 25345094
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal Acid Lipase Deficiency: Therapeutic Options.
Pastores GM; Hughes DA
Drug Des Devel Ther; 2020; 14():591-601. PubMed ID: 32103901
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal acid lipase deficiency: Expanding differential diagnosis.
Valayannopoulos V; Mengel E; Brassier A; Grabowski G
Mol Genet Metab; 2017; 120(1-2):62-66. PubMed ID: 27876313
[TBL] [Abstract][Full Text] [Related]
15. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease.
Balwani M; Breen C; Enns GM; Deegan PB; Honzík T; Jones S; Kane JP; Malinova V; Sharma R; Stock EO; Valayannopoulos V; Wraith JE; Burg J; Eckert S; Schneider E; Quinn AG
Hepatology; 2013 Sep; 58(3):950-7. PubMed ID: 23348766
[TBL] [Abstract][Full Text] [Related]
16. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study.
Jones SA; Rojas-Caro S; Quinn AG; Friedman M; Marulkar S; Ezgu F; Zaki O; Gargus JJ; Hughes J; Plantaz D; Vara R; Eckert S; Arnoux JB; Brassier A; Le Quan Sang KH; Valayannopoulos V
Orphanet J Rare Dis; 2017 Feb; 12(1):25. PubMed ID: 28179030
[TBL] [Abstract][Full Text] [Related]
17. Safety of sebelipase alfa for the treatment of lysosomal acid lipase deficiency.
Ezgü F
Expert Opin Drug Saf; 2022 Feb; 21(2):149-155. PubMed ID: 34664536
[TBL] [Abstract][Full Text] [Related]
18. Sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Final results of the ARISE study.
Burton BK; Feillet F; Furuya KN; Marulkar S; Balwani M
J Hepatol; 2022 Mar; 76(3):577-587. PubMed ID: 34774639
[TBL] [Abstract][Full Text] [Related]
19. Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study.
Malinová V; Balwani M; Sharma R; Arnoux JB; Kane J; Whitley CB; Marulkar S; Abel F
Liver Int; 2020 Sep; 40(9):2203-2214. PubMed ID: 32657505
[TBL] [Abstract][Full Text] [Related]
20. Managing Cardiovascular Risk in Lysosomal Acid Lipase Deficiency.
Maciejko JJ
Am J Cardiovasc Drugs; 2017 Jun; 17(3):217-231. PubMed ID: 28197978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
